Paper Details

  1. Home
  2. Paper Details

Treatment of chronic delta hepatitis with alpha-2 recombinant interferon.

Author: ActisG C, BellandoP C, BoninoF, PintusC, RizzettoM, RosinaF, SansalvadoreF, SaraccoG, SmedileA, TrincheroP

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study investigates the potential of interferon (IFN) as a treatment for chronic hepatitis D infection, a serious liver disease caused by a virus that relies on hepatitis B for survival. Previous treatments for hepatitis D have been ineffective, but the availability of large amounts of interferon offers hope for a new treatment option. The study aims to evaluate the safety and effectiveness of interferon in treating chronic hepatitis D.
Paper Details　
Original Abstract of the Article :
The Hepatitis Delta Virus (HDV), a defective ribonucleic acid virus dependent on the Hepatitis B Virus (HBV) is a cause of severe liver disease that often leads to cirrhosis and death. Since the HDV finds in the HBV infection a biological niche in which to thrive indefinitely, the major victims of i...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/s0168-8278(86)80125-8

データ提供：米国国立医学図書館（NLM）

Harnessing the Power of Alpha-2 Interferon Against Hepatitis Delta

Hepatitis Delta Virus (HDV) is a formidable foe, a stealthy virus that can lead to serious liver complications. This study explores the potential of alpha-2 interferon, a powerful weapon in the fight against viral infections, to combat HDV. Like a desert explorer seeking a hidden oasis, the researchers set out to test the efficacy of this drug in treating chronic HDV hepatitis. This study delves into the world of viral hepatitis, a challenging field where researchers are constantly seeking new and effective treatments. The authors present a preliminary report on the tolerance and efficacy of alpha-2 interferon in patients with chronic HDV hepatitis. Their findings, like a guiding star in the night sky, offer hope for new therapeutic avenues in the treatment of this debilitating disease.

Alpha-2 Interferon Shows Promise in the Fight Against HDV

This study provides initial evidence that alpha-2 interferon may be a viable treatment option for chronic HDV hepatitis. The researchers observed that the drug was well-tolerated and demonstrated promising signs of efficacy. This finding is like a spring of water in the desert, a source of hope and potential relief for patients suffering from HDV.

Understanding the Role of Interferon in Viral Hepatitis

The research sheds light on the complex interplay between interferon, a key player in the immune response, and viral hepatitis. Interferon's ability to inhibit viral replication offers a potential avenue for treating a range of viral infections. This study is a testament to the ongoing search for effective treatments against debilitating viral diseases. The researchers' efforts are like a tireless caravan, journeying across the vast desert of medical research, seeking new solutions to combat these formidable adversaries.

Dr.Camel's Conclusion

This study offers a promising starting point for further research into the potential of alpha-2 interferon in treating chronic HDV hepatitis. The desert of viral hepatitis is vast and challenging, but this research represents a crucial step toward developing effective therapies for patients suffering from this complex disease.

Date :
  1. Date Completed 1987-08-05
  2. Date Revised 2019-08-17
Further Info :

Pubmed ID

3298410

DOI: Digital Object Identifier

10.1016/s0168-8278(86)80125-8

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.